Drug Trial Radar · NCT06716814
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Actual
Start
Mar 6, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- PSI CRO
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), PK comparison study (Sobi.BIVV001-003) or SHINE study (Sobi.BIVV001-004). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first). The study starts with the Baseline Visit, which will be done in connection to the end of treatment at the EoT/EoS visit (or equivalent) in the respective parent study. Subsequent study visits (on site or phone call) will be done approximately every 13 weeks until End of Treatment. An End of Study safety phone call will be done 14 (+7) days after the End of Treatment Visit.
Conditions
- Haemophilia A (Moderate or Severe)
Interventions
Efanesoctocog alfaDrug
Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of injections to treat a bleeding episodeTime frame: From enrollment and up to 52 weeks
- Total dose to treat a bleeding episodeTime frame: From enrollment and up to 52 weeks
- Adverse events (AEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for treated bleeding episodesTime frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for treated bleeding episodes by type of bleedTime frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for treated bleeding episodes by location of bleedTime frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for all bleeding episodesTime frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for all bleeding episodes by type of bleedTime frame: From enrollment and up to 52 weeks
- Annualized bleeding rate (ABR) for all bleeding episodes by location of bleedTime frame: From enrollment and up to 52 weeks
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Sobi Investigational Site
Plovdiv, Bulgaria
Sobi Investigational Site
Sofia, Bulgaria
Sobi Investigational Site
Brest, France
Sobi Investigational Site
Bron, France
Sobi Investigational Site
Lille, France
Sobi Investigational Site
Athens, Greece
Sobi Investigational Site
Catanzaro, Italy
Sobi Investigational Site
Florence, Italy
Sobi Investigational Site
Milan, Italy
Sobi Investigational Site
Naples, Italy
Sobi Investigational Site
Parma, Italy
Sobi Investigational Site
Rome, Italy
Sobi Investigational Site
Rozzano, Italy
Sobi Investigational Site
Vicenza, Italy
Sobi Investigational Site
Oslo, Norway
Sobi Investigational Site
A Coruña, Spain
Sobi Investigational Site
Zaragoza, Spain
Sobi Investigational Site
Gothenburg, Sweden
Sobi Investigational Site
Lund, Sweden
Sobi Investigational Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.